Sanofi’s presence in Tunisia is operational via the following 2 structures:

SAT(Sanofi-Aventis Tunisia)
Opella Healthcare Tunisia, new entity created in 2021
This reorganization is part of a better understanding of the therapeutic solutions offered by Sanofi in Tunisia.

Sanofi-Aventis Tunisia (SAT) is in charge of promoting  specialty medicine products  and more particularly in the following therapeutic areas:

Diabetes and cardiovascular;
Oncology;
Rare Diseases
Antibiotic therapy and anti-inflammatories
Central nervous system
Immunology
Vaccines
The activities of Opella Healthcare Tunisia concern pharmaceutical specialties related to  family health  and in particular:

Pain;
Digestive and transit problems;
sleep disorders;
Winter ailments: flu, cough, sore throat, colds
Main indicators

33 million units produced in 2020
13% of production is for export
90% of the medicines distributed are produced locally
600 employees
1st private investor in medical research
Sanofi in Tunisia remains a major player in the pharmaceutical industry in Tunisia.

Sanofi retains its 2 production entities Winthrop Pharma Tunisia and Sanofi-Aventis Pharma Tunisia.